{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T14:18:33Z","timestamp":1794838713140,"version":"4.9.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.phrs.2026.108439","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T14:52:03Z","timestamp":1788706323000},"page":"108439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["From target engagement to translational disconnect: A systematic review and narrative synthesis of direct tau-targeted clinical trials in Alzheimer\u2019s disease and primary tauopathies"],"prefix":"10.1016","volume":"232","author":[{"given":"Ling","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruodi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4769-9712","authenticated-orcid":false,"given":"Yun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.phrs.2026.108439_bib1","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00401-022-02480-x","article-title":"Selective tau seeding assays and isoform-specific antibodies define neuroanatomic distribution of progressive supranuclear palsy pathology arising in Alzheimer\u2019s disease","volume":"144","author":"Coughlin","year":"2022","journal-title":"Acta Neuropathol. (Berl. )"},{"issue":"3","key":"10.1016\/j.phrs.2026.108439_bib2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jnnp-2014-308004","article-title":"Divergent CSF \u03c4 alterations in two common tauopathies: Alzheimer\u2019s disease and progressive supranuclear palsy","volume":"86","author":"Wagshal","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.phrs.2026.108439_bib3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol. (Berl. )"},{"issue":"4","key":"10.1016\/j.phrs.2026.108439_bib4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"issue":"1","key":"10.1016\/j.phrs.2026.108439_bib5","article-title":"Alzheimer\u2019s disease drug development pipeline: 2022","volume":"8","author":"Cummings","year":"2022","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv."},{"issue":"1","key":"10.1016\/j.phrs.2026.108439_bib6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13024-023-00601-y","article-title":"Common mouse models of tauopathy reflect early but not late human disease","volume":"18","author":"Wenger","year":"2023","journal-title":"Mol. Neurodegener."},{"issue":"8","key":"10.1016\/j.phrs.2026.108439_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70578","article-title":"Twenty years of therapeutic development in tauopathy mouse models: a scoping review","volume":"21","author":"Langness","year":"2025","journal-title":"Alzheimers Dement."},{"issue":"9868","key":"10.1016\/j.phrs.2026.108439_bib8","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","article-title":"Frailty in elderly people","volume":"381","author":"Clegg","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.phrs.2026.108439_bib9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40262-025-01494-4","article-title":"Influence of ageing on the pharmacodynamics and pharmacokinetics of chronically administered medicines in geriatric patients: a review","volume":"64","author":"Ngcobo","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2026.108439_bib10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"134","author":"Page","year":"2021","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.phrs.2026.108439_bib11","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.phrs.2026.108439_bib12","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","article-title":"Safety and efficacy of semorinemab in individuals with prodromal to mild alzheimer disease: a randomized clinical trial","volume":"79","author":"Teng","year":"2022","journal-title":"JAMA Neurol."},{"issue":"14","key":"10.1016\/j.phrs.2026.108439_bib13","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207663","article-title":"Randomized Phase II study of the safety and efficacy of semorinemab in participants with mild-to-moderate alzheimer disease: lauriet","volume":"101","author":"Monteiro","year":"2023","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.phrs.2026.108439_bib14","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/brain\/awad024","article-title":"Tilavonemab in early Alzheimer\u2019s disease: results from a phase 2, randomized, double-blind study","volume":"146","author":"Florian","year":"2023","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.phrs.2026.108439_bib15","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/s43587-023-00523-w","article-title":"TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer\u2019s disease","volume":"3","author":"Shulman","year":"2023","journal-title":"Nat. Aging"},{"issue":"8","key":"10.1016\/j.phrs.2026.108439_bib16","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41591-021-01455-x","article-title":"Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial","volume":"27","author":"Dam","year":"2021","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.phrs.2026.108439_bib17","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S1474-4422(20)30489-0","article-title":"Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial","volume":"20","author":"H\u00f6glinger","year":"2021","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108439_bib18","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208061","article-title":"Assessment of efficacy and safety of zagotenemab: results from PERISCOPE-ALZ, a phase 2 study in early symptomatic Alzheimer disease","volume":"102","author":"Fleisher","year":"2024","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.phrs.2026.108439_bib19","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","article-title":"ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer\u2019s disease","volume":"1","author":"Novak","year":"2021","journal-title":"Nat. Aging"},{"key":"10.1016\/j.phrs.2026.108439_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105940","article-title":"Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer\u2019s disease: a phase 1b\/2a, multicentre, double-blind, randomised, placebo-controlled study","volume":"120","author":"Sol","year":"2025","journal-title":"eBioMedicine"},{"issue":"12","key":"10.1016\/j.phrs.2026.108439_bib21","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jamaneurol.2023.3861","article-title":"Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial","volume":"80","author":"Edwards","year":"2023","journal-title":"JAMA Neurol."},{"issue":"10062","key":"10.1016\/j.phrs.2026.108439_bib22","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial","volume":"388","author":"Gauthier","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.phrs.2026.108439_bib23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3233\/JAD-170560","article-title":"Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer\u2019s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial","volume":"61","author":"Wilcock","year":"2018","journal-title":"J. Alzheimers Dis. JAD"},{"key":"10.1016\/j.phrs.2026.108439_bib24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13195-024-01456-1","article-title":"Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer\u2019s disease: a systematic review","volume":"16","author":"Oosthoek","year":"2024","journal-title":"Alzheimers Res. Ther."},{"issue":"386","key":"10.1016\/j.phrs.2026.108439_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal2029","article-title":"Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy","volume":"9","author":"Yanamandra","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.phrs.2026.108439_bib26","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.3390\/ijms23105404","article-title":"Transgenic mouse models of Alzheimer\u2019s disease: an integrative analysis","volume":"23","author":"Sanchez-Varo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.phrs.2026.108439_bib27","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ajpath.2017.01.022","article-title":"Tau antibody targeting pathological species blocks neuronal uptake and interneuron propagation of tau in vitro","volume":"187","author":"Nobuhara","year":"2017","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.phrs.2026.108439_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.867457","article-title":"PBPK-PD modeling for the preclinical development and clinical translation of tau antibodies for Alzheimer\u2019s disease","volume":"13","author":"Bloomingdale","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108439_bib29","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1038\/s41598-019-41105-4","article-title":"Antibody-mediated clearance of tau in primary mouse microglial cultures requires Fc\u03b3-receptor binding and functional lysosomes","volume":"9","author":"Andersson","year":"2019","journal-title":"Sci. Rep."},{"issue":"40, 2017","key":"10.1016\/j.phrs.2026.108439_bib30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev-neuro-072116-031153","article-title":"Propagation of Tau Aggregates and Neurodegeneration","volume":"40","author":"Goedert","year":"2017","journal-title":"Annu. Rev. Neurosci."},{"issue":"2","key":"10.1016\/j.phrs.2026.108439_bib31","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/brain\/awaa373","article-title":"CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer\u2019s disease","volume":"144","author":"Horie","year":"2021","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.phrs.2026.108439_bib32","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"12","key":"10.1016\/j.phrs.2026.108439_bib33","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1038\/jcbfm.2013.160","article-title":"Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood-brain barrier","volume":"33","author":"St-Amour","year":"2013","journal-title":"J. Cereb. Blood Flow. Metab. J. Int. Soc. Cereb. Blood Flow. Metab."},{"key":"10.1016\/j.phrs.2026.108439_bib34","doi-asserted-by":"crossref","DOI":"10.1517\/14728222.2015.1042364","article-title":"Blood-brain barrier endogenous transporters as therapeutic targets: A new model for small molecule CNS drug discovery","volume":"19","author":"Pardridge","year":"2015","journal-title":"Expert. Opin. Ther. Targets"},{"key":"10.1016\/j.phrs.2026.108439_bib35","series-title":"Topline results from CELIA: A Phase 2 study to evaluate the tau-targeting antisense oligonucleotide diranersen (BIIB080) in patients with early Alzheimer\u2019s disease. In","author":"Mummery","year":"2026"},{"issue":"1","key":"10.1016\/j.phrs.2026.108439_bib36","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrn.2015.1","article-title":"Tau in physiology and pathology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.phrs.2026.108439_bib37","article-title":"Lessons from Tau-Deficient Mice","volume":"2012","author":"Ke","year":"2012","journal-title":"Int. J. Alzheimers Dis."},{"issue":"4","key":"10.1016\/j.phrs.2026.108439_bib38","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","article-title":"The Cellular Phase of Alzheimer\u2019s Disease","volume":"164","author":"De Strooper","year":"2016","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.phrs.2026.108439_bib39","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug Transport across the Blood\u2013Brain Barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J. Cereb. Blood Flow. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2026.108439_bib40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1124\/jpet.113.212407","article-title":"Pharmacology of a Central Nervous System Delivered 2\u2032-O-Methoxyethyl\u2013Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates","volume":"350","author":"Rigo","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2026.108439_bib41","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3389\/fnagi.2019.00373","article-title":"Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain","volume":"11","author":"Pardridge","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.phrs.2026.108439_bib42","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","article-title":"Nanoparticle-mediated brain drug delivery: Overcoming blood\u2013brain barrier to treat neurodegenerative diseases","volume":"235","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.phrs.2026.108439_bib43","first-page":"187","article-title":"Nasal drug delivery-possibilities, problems and solutions","volume":"87","author":"Illum","year":"2003"},{"issue":"7","key":"10.1016\/j.phrs.2026.108439_bib44","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv. Drug. Deliv. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2026.108439_bib45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"al et. Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.phrs.2026.108439_bib46","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826003543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826003543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T13:34:49Z","timestamp":1794836089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826003543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":46,"alternative-id":["S1043661826003543"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108439","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From target engagement to translational disconnect: A systematic review and narrative synthesis of direct tau-targeted clinical trials in Alzheimer\u2019s disease and primary tauopathies","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108439","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108439"}}